FKBP5, SERT and COMT mRNA expressions in the peripheral leukocytes during menstruation cycle in healthy reproductive females

Neuroscience Letters

Volumn 434, Issue 1, 2008, Pages 124-128

  Kinouchi, Sawako ^a   Iga, Jun Ichi ^a   Ueno, Shu Ichi ^a   Yamauchi, Ken ^a   Numata, Shusuke ^a   Song, Hongwei ^a   Sumitani, Satsuki ^a   Shibuya Tayoshi, Sumiko ^a   Haku, Mari ^a   Yasui, Toshiyuki ^a   Irahara, Minoru ^a   Morita, Kyoko ^a   Rokutan, Kazuhito ^a   Ohmori, Tetsuro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

HADS; Leukocytes; Menstrual cycle; mRNA expression; Real time PCR method

Indexed keywords

CATECHOL METHYLTRANSFERASE; FK 506 BINDING PROTEIN; SEROTONIN TRANSPORTER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLICULAR PHASE; GENE EXPRESSION; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LEUKOCYTE; LUTEAL PHASE; MENSTRUAL CYCLE; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; ANXIETY; ANXIETY DISORDERS; BIOLOGICAL MARKERS; CATECHOL O-METHYLTRANSFERASE; CATECHOLAMINES; DEPRESSION; DEPRESSIVE DISORDER; FEMALE; FOLLICULAR PHASE; HUMANS; LEUKOCYTES; LUTEAL PHASE; MENSTRUAL CYCLE; PREMENSTRUAL SYNDROME; REFERENCE VALUES; REPRODUCTION; RNA, MESSENGER; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TACROLIMUS BINDING PROTEINS;

EID: 40649127657     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.01.039     Document Type: Article

References (27)

1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental, Disorders. 4th ed. (1994), American Psychiatric Association, Washington, DC
2. American Psychiatric Association, Diagnostic and Statistical Manual of Mental, Disorders. 4th ed. (2000), American Psychiatric Association, Washington, DC text, revision
3. Ashby Jr. C.R., Carr L.A., Cook C.L., Steptoe M.M., and Franks D.D. Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome. Biol. Psychiatry 24 (1988) 225-233
4. Baughman G., Wiederrecht G.J., Chang F., Martin M.M., and Bourgeois S. Tissue distribution and abundance of human FKBP51, an FK506-binding protein that can mediate calcineurin inhibition. Biochem. Biophys. Res. Commun. 232 (1997) 437-443
5. Bertolino A., Caforio G., Blasi G., De Candia M., Latorre V., Petruzzella V., Altamura M., Nappi G., Papa S., Callicott J.H., Mattay V.S., Bellomo A., Scarabino T., Weinberger D.R., and Nardini D.M. Interaction of COMT(Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry 161 (2004) 1798-1805
6. Binder E.B., Salyakina D., Lichtner P., Wochnik G.M., Ising M., Pütz B., Papiol S., Seaman S., Lucae S., Kohli M.A., Nickel T., Künzel H.E., Fuchs B., Majer M., Pfennig A., Kern N., Brunner J., Modell S., Baghai T., Deiml T., Zill P., Bondy B., Rupprecht R., Messer T., Köhnlein O., Dabitz H., Brückl T., Müller N., Pfister H., Lieb R., Mueller J.C., Lõhmussaar E., Strom T.M., Bettecken T., Meitinger T., Uhr M., Rein T., Holsboer F., and Muller-Myhsok B. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 36 (2004) 1319-1325
7. Bjelland I., Dahl A.A., Haug T.T., and Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J. Psychosom. Res. 52 (2002) 69-77
8. Cohen L.S., Soares C.N., Yonkers K.A., Bellew K.M., Bridges I.M., and Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom. Med. 66 (2004) 707-713
9. Dimmock P.W., Wyatt K.M., Jones P.W., and O'Brien P.M.S. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 356 (2000) 1131-1136
10. Halbreich U., Borenstein J., Pearlstein T., and Kahn L.S. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 28 (2003) 1-23
11. Hsiao C.C., Liu C.Y., and Hsiao M.C. No correlation of depression and anxiety to plasma estrogen and progesterone levels in patients with premenstrual dysphoric disorder. Psychiatry Clin. Neurosci. 58 (2004) 593-599
12. Hubler T.R., Denny W.B., Valentine D.L., Cheung-Flynn J., Smith D.F., and Scammell J.G. The FK506-binding immunophilin FKBP51 is transcriptionally regulated by progestin and attenuates progestin responsiveness. Endocrinology 144 (2003) 2380-2387
13. Hylan T.R., Sundell K., and Judge R. The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom and France. J. Womens Health Gender-Based Med. 8 (1999) 1043-1052
14. Iga J., Ueno S., Yamauchi K., Motoki I., Tayoshi S., Ohta K., Song H., Morita K., Rokutan K., and Ohmori T. Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci. Lett. 389 (2005) 12-16
15. Iga J., Ueno S., Yamauchi K., Numata S., Motoki I., Tayoshi S., Kinouchi S., Ohta K., Song H., Morita K., Rokutan K., Tanabe H., Sano A., and Ohmori T. Gene expression and association analysis of LIM (PDLIM5) in major depression. Neurosci. Lett. 400 (2006) 203-207
16. Jiang H., Xie T., Ramsden D.B., and Ho S.L. Human catechol-O-methyltransferase down-regulation by estradiol. Neuropharmacology 45 (2003) 1011-1018
17. Kester H.A., van der Leede B.M., van der Saag P.T., and van der Burg B. Novel progesterone target genes identified by an improved differential display technique suggest that progestin-induced growth inhibition of breast cancer cells coincides with enhancement of differentiation. J. Biol. Chem. 26 (1997) 16637-16643
18. Lai I.C., Hong C.J., and Tsai S.J. Expression of cAMP response element-binding protein in major depression before and after antidepressant treatment. Neuropsychobiology 48 (2003) 182-185
19. S. Numata, S. Ueno, J. Iga, K. Yamauchi, S. Hongwei, R. Hashimoto, M. Takeda, H. Kunugi, M. Itakura, T. Ohmori, TGFBR2 gene expression and genetic association with schizophrenia, J. Psychiatr. Res., in press.
20. Rapkin A.J., Edelmuth E., Chang L.C., Reading A.E., McGuire M.T., and Su T.-P. Whole-blood serotonin in premenstrual syndrome. Obstet. Gynecol. 70 (1987) 533-537
21. 4 dopamine receptor messenger RNA expression in lymphocytes from patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 26 (2002) 1155-1160
22. Sundell G., Milsom I., and Andersch B. Factors influencing the prevalence and severity of dysmenorrhoea in young women. Br. J. Obstet. Gynaecol. 97 (1990) 588-594
23. Tenhunen J., Salminen M., Lundström K., Kiviluoto T., Savolainen R., and Ulmanen I. Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur. J. Biochem. 223 (1994) 1049-1059
24. Tunbridge E.M., Harrison P.J., and Weinberger D.R. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol. Psychiatry 60 (2006) 141-151
25. Vermeer H., Hendriks-Stegeman B.I., van der Burg B., van Buul-Offers S.C., and Jansen M. Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid, sensitivity, potency, and bioavailability. J. Clin. Endocrinol. Metab. 88 (2003) 277-284
26. Xie T., Ho S.L., and Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol. Pharmacol. 56 (1999) 31-38
27. Zigmond A.S., and Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67 (1983) 361-370